Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPantheon Resources plc Share News (PANR)

Share Price Information for Pantheon Resources plc (PANR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.60
Bid: 28.60
Ask: 28.75
Change: -2.95 (-9.35%)
Spread: 0.15 (0.524%)
Open: 31.55
High: 31.55
Low: 28.10
Prev. Close: 31.55
PANR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Pelatro plummets on delisting plans

Tue, 29th Aug 2023 10:23

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pantheon Resources PLC, up 13% at 15.31p, 12-month range 10.10p-136.00p. The oil and gas company focused on onshore operations in the US receives independent expert report. It says the report provides an estimate of contingent resources recoverable from its 100% working interest Kodiak project, formerly known as Theta West. The company adds that the report confirms best estimate contingent resource estimates totalling 962 million barrels for Kodiak Field. Chief Executive Officer Jay Cheatham says: "This really is a big deal. A credible third-party estimate of nearly one billion barrels of recoverable liquids for a company the size of Pantheon is an incredible achievement, validating our geological model."

----------

Faron Pharmaceuticals Ltd, up 11% at 299.80p, 12-month range 155.00p-395.00p. The clinical-stage biopharmaceutical company says that the US Food & Drug Administration has granted orphan drug designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. Orphan drug designation gives intellectual property cover and data protection to investigational drugs, as well as potential tax credits on eventual US sales of an approved orphan drug. Bexmarilimab is an immunotherapy designed to overcome resistance to existing treatments for acute myeloid leukaemia, a type of cancer, and myelodysplastic syndromes. "Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to develop bexmarilimab as a potential treatment for AML," says Chief Medical Officer Marie-Louise Fjallskog. Also reports no revenue in the first half of 2023, unchanged year-on-year. Pretax loss widens to EUR13.7 million from EUR13.1 million.

----------

AIM - LOSERS

----------

Pelatro PLC, down 73% at 0.80p, 12-month range 0.69p-24.50p. The marketing software provider decides to cancel shares from AIM market in London, citing costs, management time required, and regulatory burden of maintaining a listing. It will announce schedule for the cancellation, including date of general meeting for shareholders to vote on the plan, "in due course". It will put in place a matched bargain facility to help shareholders buy and sell shares after the delisting. Nic Hellyer resigns as chief financial officer. Leaves board immediately but will remain with company to help with the share cancellation and financial reports. Pelatro says Bangalore-based finance function remains unaffected.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Nov 2021 16:06

Pantheon gets $1.5m from shareholder as it seeks funding solution

(Sharecast News) - Pantheon Resources has entered into a short-term draw down facility of $1.5m with an existing shareholder, it announced on Wednesday.

Read more
17 Nov 2021 12:09

TRADING UPDATES: Wincanton Primark deal; Mode Global cuts bitcoin fees

TRADING UPDATES: Wincanton Primark deal; Mode Global cuts bitcoin fees

Read more
20 Oct 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
11 Oct 2021 11:23

IN BRIEF: Pantheon Infrastructure aims for GBP300 million raise in IPO

IN BRIEF: Pantheon Infrastructure aims for GBP300 million raise in IPO

Read more
11 Aug 2021 19:21

TRADING UPDATES: Pantheon farmout talks; Danakali to delist in London

TRADING UPDATES: Pantheon farmout talks; Danakali to delist in London

Read more
16 Jul 2021 12:24

Pantheon in farmout talks as Alaskan well resource upgrade lifts stock

Pantheon in farmout talks as Alaskan well resource upgrade lifts stock

Read more
16 Jul 2021 12:03

Friday broker round-up

(Sharecast News) - Pantheon Resources: Canaccord Genuity keeps at speculative buy but hikes target price from 115.0p to 170.0p.

Read more
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more
17 May 2021 17:49

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

TRADING UPDATES: Wey takeover edges closer; Acorn in strategy switch

Read more
27 Apr 2021 11:44

88 Energy starts tests at Alaska well after "encouraging" map results

88 Energy starts tests at Alaska well after "encouraging" map results

Read more
19 Apr 2021 13:52

Monday broker round-up

(Sharecast News) - tinyBuild: Berenberg initiates at buy with a target price of 295p.

Read more
19 Apr 2021 12:56

IN BRIEF: Pantheon Resources shares tumble amid Talitha blow

IN BRIEF: Pantheon Resources shares tumble amid Talitha blow

Read more
19 Apr 2021 11:32

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

AIM WINNERS & LOSERS: Pantheon falls after Alaska drilling results

Read more
6 Apr 2021 11:30

TRADING UPDATES: Redcentric and Argentex to post solid annual results

TRADING UPDATES: Redcentric and Argentex to post solid annual results

Read more
30 Mar 2021 20:33

TRADING UPDATES: Numis expects interim revenue rise; Dods profit swing

TRADING UPDATES: Numis expects interim revenue rise; Dods profit swing

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.